home All News open_in_new Full Article

Wegovy als Tablette: Chancen für Novo Nordisk, Risiken für Ypsomed

Abnehmen - Die US-Zulassung für eine Tabletten-Version des Abnehm-Medikaments Wegovy treibt die Aktien von Novo Nordisk kräftig an. Für Ypsomed wirft die neue Darreichungsform hingegen Fragen auf.


today 1 week ago attach_file Other

attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Politics
attach_file Society
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Society
attach_file Other
attach_file Other
attach_file Other
attach_file Other


ID: 2734797731
Add Watch Country

arrow_drop_down